Abstracts Archive - Page 1632 of 2425 - ACR Meeting Abstracts

Abstract Number: 3226 • 2016 ACR/ARHP Annual Meeting
Maintenance of Clinical Remission and Radiographic Non-Progression with MTX after Completion of 1 Year Initial Treatment with Certolizumab Pegol in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Tatsuya Atsumi², Kazuhiko Yamamoto³, Tsutomu Takeuchi⁴, Hisashi Yamanaka⁵, Naoki Ishiguro⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Pauline Ralston¹¹, Désirée van der Heijde¹², Nobuyuki Miyasaka^13,14 and Takao Koike¹⁵, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³The University of Tokyo, Tokyo, Japan, ⁴Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁵Tokyo Women's Medical University, Tokyo, Japan, ⁶Nagoya University, Nagoya, Japan, ⁷Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Japan, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹Hays Pharma, London, United Kingdom, ¹²Leiden University Medical Center, Leiden, Netherlands, ¹³Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Sapporo Medical Center NTT EC, Sapporo, Japan
Background/Purpose: The efficacy and safety of certolizumab pegol (CZP) treatment in combination with dose-optimized MTX in Japanese MTX-naïve early RA patients (pts) with poor prognostic…
Abstract Number: 3227 • 2016 ACR/ARHP Annual Meeting
Modelling Primary Sjögren’s Syndrome Using Salivary Gland Stem Cells
Sarah Pringle¹, Hendrika Bootsma², Arjan Vissink³, Fred K.L. Spijkervet⁴, Robert Coppes⁵ and Frans G.M. Kroese⁶, ¹Rheumatology and Clinical Immunology, University Medical Centrum Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands, ³Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Radiation Oncology and Cell Biology, University Medical Centrum Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Primary Sjögren’s Syndrome (pSS) is characterized by lymphocytic infiltration of salivary glands. Unclear interactions between infiltrating cells and salivary gland ductal cells cause reduced…
Abstract Number: 3228 • 2016 ACR/ARHP Annual Meeting
Specific T Cell and B Cell Distributions Characterize Subgroups of Patients with Primary Sjögren’s Syndrome and Are Associated with Disease Activity and Pro-Inflammatory Cytokine Expression
Lucas Le Lann¹, Quentin Simon¹, Christophe Jamin¹, Maria Orietta Borghi², Lorenzo Beretta³, Ricard Cervera⁴, Alain Saraux⁵, Divi Cornec¹, Rik Lories⁶, Carlo Chizzolini⁷, Marta E. Alarcon Riquelme⁸, Jacques-Olivier Pers¹ and on behalf of the PRECISESADS Consortium, ¹INSERM ERI29, EA2216, Université de Brest, Labex IGO, CHRU Morvan, Brest, France, ²University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ³Rheumatology, Milan, Italy, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, KU Leuven and University Hospitals Leuven., Leuven, Belgium, ⁷University hospital of Geneva, Geneva, Switzerland, ⁸Centro de Genomica e Investigación Oncológica, Pfizer-University of Granada-Junta de Andalucía, Granada, Spain
Background/Purpose : The goal of the IMI PRECISESADS project is to reclassify individuals affected by systemic autoimmune diseases (SADs) into clusters of molecular, instead of…
Abstract Number: 3229 • 2016 ACR/ARHP Annual Meeting
Bone Morphogenetic Protein 6 Receptor Inhibition Restores Salivary Gland Function in a Mouse Model of Primary Sjögren’s Syndrome
Hongen Yin¹, Lovika Kalra¹, Arif Karim¹, Zhennan Lai¹, Maria Guimaro¹, Lauren Aber¹, Bill Swaim¹, Sandra Afione¹, Alexandria Voigt², Cuong Nguyen³, Paul Yu⁴, Donald Bloch⁵ and John A. Chiorini¹, ¹Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ²Department of Pathology and Infectious Diseases, University of Florida, Gainesville, FL, ³Department of Pathology and Infectious Diseases, University of Florida, Bethesda, MD, ⁴Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Center for Immunology and Inflammatory Diseases and the Division of Rheumatology, Allergy, and Immunology of the Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Methods: Results: Elevated BMP6 was found in 63/80 (78.8%) of pSS patients examined in this study. In humans, ALK2 and ALK3 receptors…
Abstract Number: 3230 • 2016 ACR/ARHP Annual Meeting
Genome-Wide Association Study Identifies Novel Sjögren’s Syndrome Risk Loci in the Regions of NAB1, TYK2, and PTTG1-mir146a
Christopher J. Lessard¹, Indra Adrianto¹, John Ice¹, Astrid Rasmussen², Kiely Grundahl³, Jennifer A. Kelly⁴, R. Hal Scofield¹, Simon Bowman⁵, Susan Lester⁶, Per Eriksson⁷, Maija-Leena Eloranta⁸, Johan G. Brun⁹, Lasse G. Goransson¹⁰, Erna Harboe¹⁰, Marika Kvarnström¹¹, Michael T. Brennan¹², James Chodosh¹³, Raj Gopalakrishnan¹⁴, Andrew J.W. Huang¹⁵, Pamela Hughes¹⁶, David M. Lewis¹⁷, Michael D. Rohrer¹⁸, Donald U. Stone¹⁹, Nelson L. Rhodus²⁰, Barbara M. Segal²¹, Lida Radfar²², A. Darise Farris²³, Joel M. Guthridge²⁴, Patrick M. Gaffney¹, Judith A. James¹, John B. Harley²⁵, Lars Rönnblom⁸, Juan-Manuel Anaya²⁶, Deborah S. Cunninghame-Graham²⁷, Timothy J. Vyse²⁸, Ilias Alevizos²⁹, Xavier Mariette³⁰, Roald Omdal¹⁰, Marie Wahren-Herlenius³¹, Torsten Witte³², Roland Jonsson³³, Maureen Rischmueller³⁴, Lindsey A. Criswell³⁵, Courtney G. Montgomery¹, Wan-Fai Ng³⁶, Gunnel Nordmark³⁷ and Kathy L. Sivils¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁴Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁶Queen Elizabeth Hospital, University of Adelaide, Adelaide, Australia, ⁷University Hospital, Rheumatology clinic, Linköping, Sweden, ⁸Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ⁹Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ¹⁰Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹¹Karolinska Institutet, Stockholm, Sweden, ¹²Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, ¹³Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁴Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁵Washington University,, St Louis, MO, ¹⁶Division of Oral and Maxillofacial Surgery, Department of Developmental and Surgical Science, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁷Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ¹⁸Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁹Dean McGee Eye Institute, Oklahoma City, OK, ²⁰Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ²¹Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ²²Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, ²³Arthritis & Immunology Program, Oklahoma Medical Research Foun, Oklahoma City, OK, ²⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁵Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Childrens Hospital, Cincinnati, OH, ²⁶Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogotá, Colombia, ²⁷Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ²⁸Division of Immunology, Infection and Inflammatory Disease, King’s College London, London, United Kingdom, ²⁹Sjögren's Syndrome Clinic, National Institute of Dental and Craniofacial Research, Bethesda, MD, ³⁰Institut National de la Santé et de la Recherche Médicale, Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ³¹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³²Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, ³³Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ³⁴Rheumatology, University of Adelaide, Adelaide, Australia, ³⁵Division of Rheumatology, UCSF, San Francisco, CA, ³⁶Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³⁷Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden
Background/Purpose: Sjögren’s syndrome (SS) is a complex autoimmune disease with both environmental and genetic factors contributing to pathophysiology. The goal of this genome-wide association study…
Abstract Number: 3231 • 2016 ACR/ARHP Annual Meeting
miR200b-5p Expression in Minor Salivary Glands (MSG): A Possible Predictor of Lymphoma Development in Sjögren’s Syndrome (SS)?
Efstathia K. Kapsogeorgou¹, Aristea Papageorgiou¹, Michael Voulgarelis² and Athanasios G. Tzioufas³, ¹Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ²Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³School of Medicine, Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: The miRNAs of the miR-200 family are critical regulators of oncogene and tumor suppressor genes. A preliminary study of several miRNAs in the MSGs…
Abstract Number: 3232 • 2016 ACR/ARHP Annual Meeting
Decreased Expression of Micro-RNA 130a and Micro-RNA 708 in Type-1 Classical Dendritic Cells of Patients with Primary SS Indicates Their Dysregulation
Maarten R. Hillen^1,2, Sofie L.M. Blokland^1,2, Elena Chouri^1,2, Ana Lopes^1,2, Aike A. Kruize², Marzia Rossato^1,2, Timothy R.D.J. Radstake^1,2 and Joel A.G. van Roon^1,2, ¹Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands
Background/Purpose: cDespite the fact that especially cDC1s are candidate key players in the activation of local T and B-cells in pSS, they have rarely been…
Abstract Number: 3233 • 2016 ACR/ARHP Annual Meeting
Determinants of Pain, Fatigue, Physical Function and Social Participation in SLE Patients, Measured with Patient Reported Outcomes Measurement Information System (PROMIS®) Computerized Adaptive Tests
Shanthini Kasturi¹, Jayme C. Burket², Jessica Berman¹, Kyriakos A. Kirou¹, Alana B. Levine¹, Lisa R. Sammaritano¹ and Lisa Mandl¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Healthcare Research Institute, Hospital for Special Surgery, New York, NY
Background/Purpose: Poor SLE outcomes have been associated with certain clinical and socio-demographic characteristics, but the determinants of patient reported outcomes (PROs) in SLE are unknown.…
Abstract Number: 3234 • 2016 ACR/ARHP Annual Meeting
Prevalence and Metric of Depression and Anxiety in Lupus: A Systematic Review and Meta-Analys
Ahmed Moustafa¹, Mohamed Hassanein², Lihi Eder³, Joan E. Wither⁴, William Fung⁵, Panayiotis Lambiris⁶ and Zahi Touma⁴, ¹Medicine, Western University, London, ON, Canada, ²Michigan State University, East Lansing, MI, ³Medicine, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Medicine, University of Toronto, Toronto, ON, Canada, ⁶University Health Network, Toronto, ON, Canada
Background/Purpose: To systematically review the literature on the: 1) prevalence of depression and anxiety in SLE patients and 2) metrics of depression and anxiety. …
Abstract Number: 3235 • 2016 ACR/ARHP Annual Meeting
Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients with Systemic Lupus Erythematosus: Up to 7 Years of Treatment Exposure
Vibeke Strand¹, Pam Berry², Sulabha Ramachandran² and James Fettiplace³, ¹Stanford University School of Medicine, Palo Alto, CA, ²GSK, Philadelphia, PA, ³GSK, Uxbridge, Middlesex, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that causes long-term organ damage over time and impairment in health-related quality of life (HRQoL).…
Abstract Number: 3236 • 2016 ACR/ARHP Annual Meeting
Socio-Demographic and Clinical Factors Influencing Generic and Disease-Specific Quality of Life in Patients with Systemic Lupus Erythematosus: Results of a Prospective Multicenter Study
Hervé Devilliers¹, Jean-François Besancenot¹, Sylvain Audia², Bernard Bonnotte³, Francois Maurier⁴, Christiane Broussolle⁵, Nadine Magy-Bertrand⁶, Denis Wahl⁷, Jean-Loup Pennaforte⁸, Thierry Martin⁹, Olivier Aumaître¹⁰, Gilles Blaison¹¹, Geraldine Muller¹, Alexis Mathian¹², Christine Binquet¹³ and Zahir Amoura¹⁴, ¹Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France, ³Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁴Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ⁵Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ⁶CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, ⁷CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, ⁸Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, ⁹Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, ¹⁰CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹¹Internal medicine departement, Colmar Hospital, Colmar, France, ¹²Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹³INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ¹⁴Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France
Background/Purpose: To describe demographic, socio-economic and lupus-related factors associated with health-related quality of life (HRQOL) in systemic lupus erythematosus (SLE), as measured by 2 generic…
Abstract Number: 3237 • 2016 ACR/ARHP Annual Meeting
Responsiveness and Its Magnitude in the 36-Item Short Form Health Survey and the Lupus Quality of Life Questionnaire in Patients with Active Disease
Stephanie Nantes¹, Jiandong Su² and Zahi Touma³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: SF-36 and LupusQoL are Health-Related Quality-of-Life (HRQoL) questionnaires used in SLE. We determined: (1) concurrent construct validity of SF-36 and LupusQoL against disease activity…
Abstract Number: 3238 • 2016 ACR/ARHP Annual Meeting
Depression Symptoms throughout the Lifespan in a Low-Income, Minority Cohort of Lupus Patients: Who Is at Risk?
Tamar Rubinstein¹, Noa Schwartz², Nicole Jordan³, Rebecca Lois⁴, Dawn Wahezi^5,6, Ruth E K Stein^7,8 and Chaim Putterman², ¹Division of Pediatric Rheumatology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY, ²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ³Montefiore Medical Center, New York, NY, ⁴Psychiatry and Pediatrics, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY, ⁵Pediatric Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁶Pediatric Rheumatology, The Children's Hospital at Montefiore, Bronx, NY, ⁷Pediatrics, Children's Hospital at Montefiore, Bronx, NY, ⁸Pediatrics, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Depression is commonly seen in lupus, but widely varying prevalence rates have been reported. This may be due to different demographics and characteristics…
Abstract Number: 3239 • 2016 ACR/ARHP Annual Meeting
Expression of IFN-Regulated Genes in Autoantibody Exposed Babies in Utero
Malin Hedlund¹, Gudny-Ella Thorlacius¹, Margarita Ivanchenko¹, Vijole Ottosson¹, Amina Ossoinak¹, Linda Lagnefeldt¹, Joanna Tingstrom¹, Alexander Espinosa¹, Lars Rönnblom², Maija-Leena Eloranta², Sven-Erik Sonesson¹ and Marie Wahren-Herlenius³, ¹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Stockholm, Sweden, ²Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ³Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Ro/SSA autoantibodies and an IFN signature are commonly present in women with Sjögren’s syndrome and SLE. During pregnancy, the autoantibodies are transported across the…
Abstract Number: 3240 • 2016 ACR/ARHP Annual Meeting
Interferon Kappa Is a Novel Type I IFN That Drives Cutaneous Inflammation in Systemic Lupus
Jasmine Stannard¹, Tamra J. Reed², Emily Myers³, Lori Lowe⁴, Mrinal Sarkar⁴, Xianying Xing⁵, Celine C. Berthier⁶, Johann Gudjonsson⁴ and J. Michelle Kahlenberg⁷, ¹Int. Medicine/Rheumatology, University of Michigan, Ann Arbor, MI, ²Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Rheumatology, Georgetown University, Washington, DC, ⁴Dermatology, University of Michigan, Ann Arbor, MI, ⁵Dermatology, University of Michigan, University of Michigan, Ann Arbor, MI, ⁶Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ⁷Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are disfiguring, scarring, difficult to treat, and affect up to 70% of patients with systemic lupus erythematosus (SLE). Type…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].